Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines
Clinical Infectious Diseases · 13.01.2023 · 76 (2) · 338-341
DOI: 10.1093/cid/ciac788 ↗Kurz gefasst
Leitlinie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 22.09.2022. Verfasst von Jennifer H Ku und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: Mycobacterium Infections, Nontuberculous, Bronchiectasis, Communicable Diseases, Opportunistic Infections. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: COPD Foundation.
Themen: Patientensicherheit
Abstract (Originalsprache)
Among 1038 participants with pulmonary Mycobacterium avium complex and 120 with Mycobacterium abscessus enrolled in the US Bronchiectasis and NTM Research Registry, less than half received antibiotic therapy in the 24 months before registry enrollment, of which less than half were guideline based. Adverse effects occurred in 21% of therapy recipients, of whom 33% discontinued therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
- Oregon Health & Science University-Portland State University School of Public Health, Portland, Oregon, USA.
- Department of Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Pulmonary and Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA.
ORCID-Profile: Jennifer H Ku
Förderung
- COPD Foundation
Zitieren
APA
Ku, J. H., Henkle, E., Aksamit, T. R., Barker, A., Brunton, A. E., Winthrop, K. L., & Bronchiectasis and NTM Research Registry investigators (2023). Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. Clinical Infectious Diseases, 76(2), 338-341. https://doi.org/10.1093/cid/ciac788
Vancouver
Ku JH, Henkle E, Aksamit TR, Barker A, Brunton AE, Winthrop KL, et al. Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. Clinical Infectious Diseases. 2023;76(2):338-341. doi:10.1093/cid/ciac788
BibTeX
@article{Ku2023,
author = {Ku, Jennifer H and Henkle, Emily and Aksamit, Timothy R and Barker, Alan and Brunton, Amanda E and Winthrop, Kevin L and Bronchiectasis and NTM Research Registry investigators, Bronchiectasis and NTM Research Registry investigators},
title = {Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {2},
pages = {338--341},
doi = {10.1093/cid/ciac788}
}
EUVIMED